Reata Pharmaceuticals Inc. [NASDAQ: RETA] jumped around 36.76 points on Thursday, while shares priced at $167.68 at the close of the session, up 28.08%. Reata Pharmaceuticals Inc. stock is now -17.98% down from its year-to-date (YTD) trading value. RETA Stock saw the intraday high of $177.48 and lowest of $156.99 per share. The company’s 52-week high price is 257.96, which means current price is +48.38% above from all time high which was touched on 02/05/20.
Compared to the average trading volume of 340.32K shares, RETA reached a trading volume of 1551030 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
What do top market gurus say about Reata Pharmaceuticals Inc. [RETA]?
National Securities have made an estimate for Reata Pharmaceuticals Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on November 13, 2019. While these analysts kept the previous recommendation, National Securities raised their target price to Buy. The new note on the price target was released on September 26, 2019, representing the official price target for Reata Pharmaceuticals Inc. stock. Previously, the target price had yet another raise from $116 to $139, while Leerink Partners kept a Outperform rating on RETA stock.
The Average True Range (ATR) for Reata Pharmaceuticals Inc. is set at 11.18, with the Price to Sales ratio for RETA stock in the period of the last 12 months amounting to 284.39. The Price to Book ratio for the last quarter was 24.37, with the Price to Cash per share for the same quarter was set at 18.32.
How has RETA stock performed recently?
Reata Pharmaceuticals Inc. [RETA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 29.45. With this latest performance, RETA shares gained by 1.29% in over the last four-week period, additionally sinking by -18.25% over the last 6 months – not to mention a rise of 88.94% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RETA stock in for the last two-week period is set at 62.78, with the RSI for the last a single of trading hit 68.50, and the three-weeks RSI is set at 57.59 for Reata Pharmaceuticals Inc. [RETA]. The present Moving Average for the last 50 days of trading for this stock 148.84, while it was recorded at 138.95 for the last single week of trading, and 165.67 for the last 200 days.
Reata Pharmaceuticals Inc. [RETA]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Reata Pharmaceuticals Inc. [RETA] shares currently have an operating margin of -1075.61. Reata Pharmaceuticals Inc.’s Net Margin is presently recorded at -1094.28.
Return on Total Capital for RETA is now -77.80, given the latest momentum, and Return on Invested Capital for the company is -100.04. Return on Equity for this stock declined to -213.35, with Return on Assets sitting at -56.47. When it comes to the capital structure of this company, Reata Pharmaceuticals Inc. [RETA] has a Total Debt to Total Equity ratio set at 148.73. Additionally, RETA Total Debt to Total Capital is recorded at 59.80, with Total Debt to Total Assets ending up at 55.98. Long-Term Debt to Equity for the company is recorded at 89.10, with the Long-Term Debt to Total Capital now at 35.82.
Reflecting on the efficiency of the workforce at the company, Reata Pharmaceuticals Inc. [RETA] managed to generate an average of -$1,318,955 per employee.Reata Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.20 and a Current Ratio set at 3.20.
Earnings analysis for Reata Pharmaceuticals Inc. [RETA]
With the latest financial reports released by the company, Reata Pharmaceuticals Inc. posted -1.14/share EPS, while the average EPS was predicted by analysts to be reported at -1.12/share.When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -1.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RETA.
Insider trade positions for Reata Pharmaceuticals Inc. [RETA]
There are presently around $2,966 million, or 81.20% of RETA stock, in the hands of institutional investors. The top three institutional holders of RETA stocks are: CPMG INC with ownership of 3,063,567, which is approximately 0% of the company’s market cap and around 0.70% of the total institutional ownership; WELLINGTON MANAGEMENT GROUP LLP, holding 3,020,924 shares of the stock with an approximate value of $395.5 million in RETA stocks shares; and VANGUARD GROUP INC, currently with $293.23 million in RETA stock with ownership of nearly 3.362% of the company’s market capitalization.
Positions in Reata Pharmaceuticals Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 113 institutional holders increased their position in Reata Pharmaceuticals Inc. [NASDAQ:RETA] by around 2,850,631 shares. Additionally, 104 investors decreased positions by around 2,183,965 shares, while 35 investors held positions by with 17,616,662 shares. The mentioned changes placed institutional holdings at 22,651,258 shares, according to the latest SEC report filing. RETA stock had 35 new institutional investments in for a total of 837,553 shares, while 31 institutional investors sold positions of 466,022 shares during the same period.